Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
 |
Food and Drug Administration (FDA),U.S. Department of Health and Human Services - January 5, 1998
Today's Federal Register carries a notice of the availability of this draft guidance. The draft guidance describes FDA's regulatory authority under the Federal Food, Drug and Cosmetic Act over the promotional practices of this growing number of PBM/medical product sponsor ventures.
"Today's proposal will help FDA keep pace with changes in the promotion of medical products, said FDA Lead Deputy Commissioner Michael Friedman. "While PBMs can be useful tools for managing health care costs, FDA wants to ensure that patients are not put at risk by improper marketing practices."
Medical product "switching" -- the substitution of one therapy for another as result of financial incentives -- is one area of concern regarding the growing trend toward drug and device sponsor ownership or partnerships with PBMs and other health care organizations. This practice could have serious health implications for patients -- particularly for those dependent on chronic therapy -- if medical decisions are influenced by incorrect or misleading information.
Concerns about drug switching and other potentially harmful promotional practices have come to light as a result of several in-depth analyses of PBM involvement in medical decision making, conducted by FDA, the Health Care Finance Administration, and the Department of Health and Human Service's Office of Inspector General. In addition, FDA has sponsored a major public hearing and issued a notice in the Federal Register seeking public comment on this issue.
After thoroughly reviewing these analyses and comments, the agency has developed this draft guidance that includes the following factors for determining whether a medical product sponsor can be held responsible for the promotional activities of a nonsubsidiary PBM that violate the Federal Food, Drug and Cosmetic Act:
The Relationship of the Sponsor and the PBM/ The nature and extent of a PBM's ties to a medical product sponsor.
Sponsor Control or Influence over the Information Content and Distribution
Provided by PBMs/ The role medical product sponsors may play in assisting PBMs in promotional activity.
FDA is seeking public comment on this proposal over the next 90 days and these comments will be considered in the development of a final guidance. Written comments may be submitted to:
Dockets Management Branch (HFA-305)
Food and Drug Administration 12420 Parklawn Drive, Rm. 1-23 Rockville, MD 20857
#####
ATTENTION TV BROADCASTERS: Please use open caption for the hearing impaired.
Distributed by AEGIS - http://www.aegis.com
980105
FD980101
SOURCE: Food and Drug Administration (FDA).
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .